Áttétes emlőrák: vizsgálatok itt: Dánia
10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Aalborg, Næstved, Soenderborg
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Copenhagen, Hillerød, Næstved, Odense C, Vejle
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - 3. fázisTaking peoplePhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Aalborg, Copenhagen Oe, Hilleroed, Odense C
- Életkor
- 18 év and over
- People
- 1180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - 1. fázisTaking peopleA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- Where
- Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 234 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06997029 · EU 2025-524334-26-01 - 1. fázisTaking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Copenhagen Oe, Odense C
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - No phaseTaking peopleDESTINY Breast Respond HER2-(Ultra)Low Europe
- Where
- Aalborg, Aarhus N, Herlev, Hillerød, Næstved, Sønderborg
- Életkor
- 18 év and over
- People
- 2295 worldwide
- Run by
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732 - 2. fázisTaking peopleA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Odense C
- Életkor
- 18 év and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - 1/2. fázisTaking peopleStudy of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
- Where
- Odense C
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521911-38-00 · EU 2025-521911-38-00 - 3. fázisTaking peopleFDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
- Where
- Aalborg, Aarhus, Copenhagen Oe, Esbjerg, Herlev, Odense C, Soenderborg, Vejle
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT06877949 · EU 2023-508591-11-00